A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

Name: A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
Published: 2021
License: Public Domain

Merck Sharp & Dohme LLC · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

advanced or metastatic solid tumors, programmed cell death-1 (pd1, pd-1), programmed death-ligand 1 (pdl1, pd-l1), interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

Related documents